Humana Inc. (HUM) recently announced its partnership with Evergreen Nephrology to launch a new valuebased kidney care program. This new program is aimed at enhancing the quality of care and improving health outcomes for patients suffering from chronic kidney diseases. This move bodes well for Humana as it will help with better retention of Medicare Advantage clients. Medicare Advantage members who qualify for this program will be able to access Evergreen Nephrology's professionals, helping them get whole-pe ...

Core Viewpoint - Humana's recent earnings report shows a mixed performance with strong revenue growth driven by Medicare Advantage, but a significant decline in adjusted earnings per share and operating income year over year [2][3][7]. Financial Performance - Adjusted EPS for Q2 2024 was $6.96, exceeding the Zacks Consensus Estimate by 18.2%, but down 22.1% from the previous year [2]. - Adjusted revenues increased by 14.2% year over year to $29.4 billion, surpassing the consensus mark by 2.6% [2]. - Total premiums rose to $28.1 billion, a 10.4% increase year over year, exceeding estimates [4]. - Total operating expenses grew by 12.2% year over year to $28.4 billion, driven by higher benefits expenses [6]. Operational Insights - The benefits expense ratio worsened by 270 basis points year over year to 89% due to rising medical costs in Medicare Advantage [5]. - Operating income fell to $1.14 billion, a decrease of 20.5% year over year, but still above estimates [7]. - The Insurance segment reported adjusted revenues of $28.4 billion, a 14.1% increase year over year, while adjusted operating income dropped 29.5% to $826 million [8]. Membership and Guidance - Total medical membership decreased by 4.8% year over year to 16.3 million, below consensus estimates [9]. - Management raised the guidance for individual Medicare Advantage membership growth to approximately 225,000, up from 150,000 [16]. - The overall revenue forecast for 2024 is now $116 billion, reflecting a 9% increase from 2023 [15]. Financial Position - As of June 30, 2024, cash and cash equivalents stood at $5.5 billion, a 17.2% increase from the end of 2023 [11]. - Long-term debt rose to $11.7 billion, a 15% increase from December 31, 2023 [11]. - Total stockholders' equity grew by 2.5% to $16.7 billion from the end of 2023 [12]. Market Position and Outlook - Humana's stock has seen a downward trend in estimates, with a consensus estimate shift of -7.02% [18]. - The company holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [20]. - Comparatively, Centene, a peer in the same industry, reported a revenue increase of 5.9% year over year, highlighting competitive dynamics within the sector [21].

UKRAINE - 2021/04/20: In this photo illustration a Johnson Controls logo is seen on a smartphone and ... [+] a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Johnson Controls stock (NYSE: HUM) currently trades around $70 per share, compared to its peak levels of over $80 seen in January 2022. While the company's stock has shed more than 10% of its value, Carrier stock (NYSE: CARR) has risen around 40% over the same period. J ...

GERMANY - 2024/02/16: In this photo illustration, a Humana Inc. logo seen displayed on a tablet. ... [+] (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Humana (NYSE: HUM) currently trades around $355 per share, nearly 30% below its peak level of $495 seen in September 2022. In comparison, UnitedHealth stock (NYSE: UNH) saw its stock rise 13% over the same period. HUM stock was trading at around $460 in June 2022, just before the Fed s ...

Core Viewpoint - Humana Inc. reported strong earnings driven by its Medicare Advantage segment, but the stock faced a significant decline due to revised guidance and increased benefit ratios, indicating investor concerns about future profitability [2][6][7]. Financial Performance - Humana's adjusted earnings per share (EPS) for Q2 2024 was $6.96, surpassing the consensus estimate of $5.85 [3][4]. - Total revenue for the quarter reached $29.54 billion, a 10.4% increase from $26.75 billion in the same period last year [3][4]. - The company reported an increase in Medicare Advantage membership to 5.62 million, up from 5.27 million a year ago [4]. Cost and Benefit Ratios - The benefit ratio increased to 89.0% from 86.3% year-over-year, reflecting higher medical expenses [5][7]. - Elevated medical cost trends, particularly in the Medicare Advantage segment, contributed to the increased benefit ratio [5][11]. Market Reaction - Following the earnings report, Humana's stock declined nearly 10% in pre-market trading, highlighting a disconnect between positive earnings and market sentiment [2][6]. - The company reaffirmed its adjusted EPS guidance of $16.00 for 2024 but reduced its GAAP EPS projection to $12.81 from $13.93 [7]. Analyst Consensus - The current analyst consensus rating for Humana is "Hold," with an average price target of $402.60, indicating a potential upside of 9.8% from the current price [8]. - Humana's short interest stands at 2.14% of the float, suggesting a moderate level of pessimism in the market [9]. Strategic Approach - Humana's strategy focuses on its Medicare Advantage business, which relies on a favorable regulatory environment and government funding [10][15]. - The company is investing in technology and data analytics to enhance operational efficiency and manage costs effectively [12][15]. - Humana is pursuing partnerships with healthcare providers to create integrated care delivery models, aiming to improve patient outcomes and optimize resource utilization [13][14].

Humana Inc. (HUM) posted second-quarter 2024 adjusted earnings per share (EPS) of $6.96, which surpassed the Zacks Consensus Estimate by 18.2%. However, the bottom line fell 22.1% year over year. Adjusted revenues improved 14.2% year over year to $29.4 billion. The top line beat the consensus mark by 2.6%. The quarterly results benefited from strong premium growth and increased service revenues, driven by expanding Medicare Advantage membership and an improved Primary Care business. However, the upside was ...

Humana (HUM) came out with quarterly earnings of $6.96 per share, beating the Zacks Consensus Estimate of $5.89 per share. This compares to earnings of $8.94 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Humana shares have lost about 11.6% since the beginning of the year versus the S&P 500's gain of 14%. There are no easy answers to this key question, but one reliable measure that can help ...

FOR MORE INFORMATION CONTACT: • Reports 2Q24 earnings per share (EPS) of $5.62 on a GAAP basis, Adjusted EPS of $6.96; reports YTD 2024 EPS of $11.74 on a GAAP basis, $14.19 on an Adjusted basis • Revises FY 2024 EPS guidance to 'approximately $12.81' (previously 'approximately $13.93') on a GAAP basis, while affirming Adjusted EPS of 'approximately $16.00'; affirms FY 2024 Insurance segment benefit ratio of approximately 90 percent • Raises 2024 individual Medicare Advantage annual membership growth by 75, ...

Shareholders who purchased shares of HUM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: July 27, 2022 to January 24, 2024 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of HUM during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lif ...

Group 1 - A class action lawsuit has been filed against Humana Inc. on behalf of shareholders who purchased common stock between July 27, 2022, and January 24, 2024, with a deadline for lead plaintiff motions set for August 2, 2024 [1][3] - The lawsuit alleges that Humana misled investors regarding its business operations, specifically downplaying pressures on adjusted earnings per share (EPS) due to increased medical costs from pent-up demand for healthcare procedures [2][5] - The lawsuit claims that when the true details about Humana's financial pressures became public, investors suffered damages [5] Group 2 - The Rosen Law Firm is investigating allegations that Humana made false and misleading statements and failed to disclose material adverse facts about its business [2][5] - Shareholders can join the class action without participating in the case, remaining as absent class members if they choose [3][6] - All representation in the lawsuit is on a contingency fee basis, meaning shareholders pay no fees or expenses [6]